ELOVL2, a novel and potential tumor antigen guided mRNA vaccine development for retroperitoneal liposarcoma

Zhenyu Wang,Tao Peng,Peidang Fan,Jiongyuan Wang,Rong Tu,Yuhong Zhou,Weiqi Lu,Hong Liang,Lijie Ma,Yong Zhang,Hanxing Tong

DOI: https://doi.org/10.21203/rs.3.rs-2688489/v1

2023-01-01

Abstract:Abstract Background The exploration of lipid metabolism dysregulation may provide novel perspectives for retroperitoneal liposarcoma (RPLS). In our study, we aimed to investigate potential tumor antigen for mRNA vaccine development and facilitate further understanding of immune landscape in RPLS, through lipid metabolism-associated genes (LMAGs) based prognostic model. Methods Gene expression profiles and corresponding clinical information of 234 cases were enrolled from two public databases and the largest retroperitoneal tumor research center of East China, including cohort-TCGA (n = 58), cohort-GSE30929 (n = 92), cohort-FD (n = 50), cohort-scRNA-seq (n = 4) and cohort-validation (n = 30). Consensus clustering analysis was performed to identify lipid metabolism-associated molecular subtypes (LMSs). A prognostic risk model containing 13 LMAGs was established using LASSO algorithm and multivariate Cox analysis in cohort-TCGA. ESTIMATE, CIBERSORT, XCELL and MCP analyses were performed to visualize the immune landscape. WGCNA was used to identify three hub genes among the 13 model LMAGs, and preliminarily validated in both cohort-GSE30929 and cohort-FD. Moreover, TIMER was used to visualize the correlation between antigen-presenting cells and potential tumor antigens. Finally, single-cell RNA-sequencing (scRNA-seq) analysis of four RPLS and immunohistochemistry were performed in cohort-validation to check the discoveries of bioinformatics analysis. Results LMS1 and LMS2 were characterized as immune-infiltrated and -excluded tumors, with significant differences in molecular features and clinical prognosis, respectively. ELOVL2 was negatively correlated with antigen-presenting cells and identified as a potential tumor antigen for mRNA vaccine development. Furthermore, ELOVL2 was enriched in LMS2 with significantly lower immunoscore and unfavorable prognosis. Finally, a high-resolution dissection through scRNA-seq was performed in four RPLS, revealing the entire tumor ecosystem and validated previous findings. Conclusions The LMS subgroups and risk model based on LMAGs proposed in our study were both promising prognostic classifications for RPLS. ELOVL2 is a potential tumor antigen linking lipid metabolism to immune regulations for mRNA vaccine development against RPLS, specifically for patients with LMS2 tumors.